HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $5.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Neutral rating on Terns Pharma (NASDAQ:TERN) and maintained a price target of $5.5.

May 14, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Terns Pharma's stock rating was reiterated as Neutral by HC Wainwright & Co. with a maintained price target of $5.5.
The reiteration of a Neutral rating and maintenance of the price target suggests no significant short-term price movement is expected. The analyst's view is already factored into the current stock price, indicating a stable outlook without immediate upside or downside risks.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100